Future Predictions for Intravenous and Subcutaneous Biologics

The prevalence of autoimmune disease patients with a mental health disorder is almost twice the number of patients without, suggesting there is a link between inflammation and conditions such as depression, anxiety disorder and bipolar disorder.

Extreme weather leads to autoimmune disease flare-ups, which can cause a loss of refrigerated medication, according to the results of recent research from the Autoimmune Association.

Jill Zouzoulas, M.D., of Tryon Medical Partners in Charlotte, North Carolina, and Jennifer Seminerio, M.D., of University of Southern Florida Health in Tampa, Florida, discussed the biologics and the pros and cons of the intravenous and subcutaneous delivery methods in Managed Healthcare Executive’s K-Cast video series.

The new biosimilar, Tyenne, was approved in both an IV and a subcutaneous forms to treat inflammatory conditions such as arthritis.

Celltrion’s application is based on data from a phase 3 trial of patients with rheumatoid arthritis comparing its biosimilar with Actemra.

The IV formulation, a monthly 30-minute, weight-based dosing option, has a wholesale acquisition cost of $2,115 per vial. It will be available in the fourth quarter.